Acadia Tops $1 Billion Revenue in 2025, NUPLAZID Volume Drives Growth
Acadia Pharmaceuticals reported Q4 and full-year 2025 results, marking over $1 billion in annual revenue for the first time. Growth was propelled by NUPLAZID’s volume gains in the quarter, reflecting continued momentum in the core business.
1. Full-Year 2025 Revenue Milestone
Acadia closed fiscal 2025 with annual revenues exceeding $1 billion, driven by strong fourth-quarter performance. This milestone reflects the company’s successful commercial expansion and strengthens its position in the neuroscience market.
2. NUPLAZID Volume Growth
Performance in the quarter was led by NUPLAZID, which saw significant volume increases across key channels. Enhanced patient adoption and targeted marketing initiatives underpinned the product’s continued uptake and contributed materially to overall revenue growth.
Related News
NVDA
Nvidia Targets $200 Billion Agentic AI Market with Vera CPU Launch
NVDA•
META
Manus Founders Seek $1B Raise to Unwind Meta's $2B AI Acquisition
META•
LCLN
Lincoln International Debuts 12.6% Up, Valued at $2.3 Billion After $421M IPO
LCLN•
NVDA
NVIDIA Forecasts Zero China Data Center Revenue, Targets $20B Vera CPU Sales
NVDA•
NBTX
Nanobiotix Halts Trading to Finalize €75 M Follow-On Offering Pricing
NBTX•
Sources
FB